Home > Result Summaries: Compounds > Herpes Simplex Vaccine Result Summaries: Herpes Simplex Vaccine GSKStudy ID Phase Title Summary (Download) 208141/001 phase 1 An open study in healthy Herpes simplex virus (HSV)-positive adults to evaluate the safety of GSK Biologicals’ candidate gD vaccine, with or without 3D MPL (1 citation(s)) 208141/002 phase 2 Study in healthy HSV positive and HSV negative adults to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals' herpes simplex (gD) candidate vaccine with or without 3D-MPL adjuvant administered according to a 0,1, 6 month schedule. (1 citation(s)) 208141/004 phase 2 A feasibility study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals' Herpes simplex candidate vaccine (gD2t), with Monophosphoryl Lipid A (MPL) and with or without Tween in initially HSV-seronegative subjects. (0 citation(s)) 208141/005 phase 3 A placebo-controlled study to evaluate the efficacy of SmithKline Beecham Biologicals’ herpes simplex candidate vaccine (gD2t) with MPL (Monophosphoryl Lipid A) to prevent genital herpes disease in healthy consorts of subjects with genital herpes disease. (2 citation(s)) 208141/006 phase 2 A double-blind, randomised study to evaluate the reactogenicity and immunogenicity of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccines (gD2t) with MPL (Monophosphoryl Lipid A), (with or without tween) in healthy HSV-seropositive subjects. (0 citation(s)) 208141/008 phase 1/2 An open randomised controlled study to evaluate in initially HSV-seronegative subjects, the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' Herpes simplex candidate vaccine (gD2t-MPL-QS21) with gD2t-Alum-MPL as control. (0 citation(s)) 208141/009 phase 1/2 An open, randomised controlled study to evaluate - in HSV-seropositive subjects - the safety, reactogenicity and immunogenicity of SmithKline Beecham Biologicals’ Herpes Simplex candidate vaccine (gD2t-MPL-QS-21), with gD-Al-MPL as control. (0 citation(s)) 208141/014 phase 1/2 A double-blind, randomized study to compare, in healthy HSV seronegative subjects, the humoral and cellular immune response of various formulations of herpes simplex candidate vaccines. (0 citation(s)) 208141/015 phase 1/2 Study to compare, in healthy HSV seronegative and HSV seropositive subjects, the humoral and cellular immune response of herpes simplex candidate vaccines containing gD from two different cell lines and using gD-Alum as control (0 citation(s)) 208141/016 phase 3 Study to evaluate the safety of GSK Biologicals’ Herpes Simplex candidate vaccine (gD2t) with MPL in HSV seropositive or seronegative subjects without genital herpes disease (3 citation(s)) 208141/017 phase 3 Safety of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccine (gD2t) with MPL & its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease (3 citation(s)) 208141/019 phase 2 A study comparing the immunogenicity of gD Alum MPL candidate herpes vaccines containing gD produced from 2 different cell lines (CHO DHFR and CHO K1) and at different gD CHO K1 production scales (300L and 600L) in healthy adult HSV seronegative subjects. (0 citation(s)) 208141/023 phase 2 A double-blind study to compare between groups, in healthy HSV-seronegative adolescent subjects, the humoral and cellular immune response and the reactogenicity of herpes simplex candidate vaccines containing gD (10µg or 20µg) and 2 doses of Al-MPL. (0 citation(s)) 208141/024 phase 3 A double blind, randomized trial comparing the immunogenicity of 3 commercial scale consistency lots of gD-Alum-MPL vaccine containing CHO K1 gD in healthy HSV seronegative adult subjects. (0 citation(s)) 208141/026 phase 2 Study comparing different doses and schedules of GSK Bio's candidate prophylactic herpes simplex virus vaccine (gD-AS04) in healthy HSV- subjects aged 10-15 and 16-18 yrs to healthy HSV- adults (aged 19-45 yrs) receiving the vaccine on a 0-1-6 mth schedule. (0 citation(s)) 208141/037 phase 3 Safety and reactogenicity of GSK Bio’s prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV 1-/2- women who received either alum-MPL or alum as placebo during one of GSK Bio’s phase III studies 208141/005, 208141/016 or 208141/017. (0 citation(s)) 208141/038 phase 3 Safety, reactogenicity, and immunogenicity of GSK Bio’s prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV 1-/2- women who received alum-MPL or alum placebo during one of GSK Bio’s Phase III studies 208141/005, 208141/016 or 208141/017. (0 citation(s)) 208141/040_ phase 3 A study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' herpes simplex candidate vaccine (gD2‑AS04) in healthy HSV seronegative and seropositive female subjects aged 10-17 years. (2 citation(s)) 208141/041 phase 3 Extension to study comparing doses and schedules of GSK's candidate prophylactic herpes simplex virus vaccine (gD-AS04) in healthy HSV- subjects aged 10-15 and 16-18 yrs to healthy HSV- adults (aged 19-45 yrs) receiving the vaccine on a 0-1-6 mth schedule. (0 citation(s)) 208141/042 phase 3 Study to Compare Immunogenicity & Safety of 3 comercial Lots of GlaxoSmithKline (GSK) Biologicals’ herpes simplex candidate Vaccine in Healthy HSV-1 & -2 Seronegative (HSV 1-/2-) Females of 10–17 y & Vaccine Immunogenicity in Healthy HSV 1-/2- Females of 10–17 y With Healthy HSV 1-/2- Adult Females (1 citation(s)) HSV Meta analyses n\a Meta analyses on pregnancy outcomes with respect to the effect of Herpes Simplex Virus (HSV) antigen and of the adjuvant (AS04) (0 citation(s))
